Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
Unexpectedly under pathological pain conditions
2023-02-13
Unexpectedly, under pathological pain conditions, inhibition of spinal glutamate transporter activity can produce antinociceptive effects. For example, intrathecal injection of the transportable inhibitor trans-pyrrolidine-2,4-dicarboxylic 5 alpha reductase inhibitor (t-PDC) or antisense oligonucle
-
During the course of our ACK inhibitor program a high
2023-02-13
During the course of our ACK1 inhibitor program, a high-throughput screening (HTS) campaign of our internal sample collection was conducted. A series of -aryl pyrimidine-5-carboxamides of the general structure () was identified. Earlier studies of the structure–activity relationship (SAR) of ident
-
AMN-107 HT receptors are distributed throughout the brain wi
2023-02-13
5-HT3 receptors are distributed throughout the brain, within the brainstem (e.g., nucleus tractus solitarius, area postrema and spinal trigeminal nucleus) and AMN-107 (e.g., hippocampus, amygdala, nucleus accumbens, putamen and caudate) (Abi-Dargham et al., 1993, Barnes et al., 1989, Bufton et al.,
-
NP118809 exemplifies three of the compounds
2023-02-10
exemplifies three of the compounds investigated in the selection for a candidate drug (CD). Our first criteria was an IC NP118809 as such did not show any genotoxicity in the SOS/umu assay, but this does not say anything about any possible genotoxicity of its metabolites or degradation products. A
-
Human lipoxygenase exists in two forms named
2023-02-10
Human 15-lipoxygenase exists in two forms, named 15-LOX-1 (also named 12/15-LOX, 15-LO-1) and 15-LOX-2. Several reports indicate that 15-LOX-1 has a pathophysiological role in respiratory inflammatory diseases, in particular asthma. Increased activity of 15-LOX-1 is displayed in the respiratory trac
-
Plant defensins Vriens et al and linear AMPs
2023-02-10
Plant defensins (Vriens et al., 2014) and linear AMPs (Domingues et al., 2015, Liu et al., 2008) have been shown to present several modes of action. Among these different mechanisms, permeabilization of the fungal membrane has been described as a secondary effect of plant defensin action (Vriens et
-
The reasons why antibiotic treatment may be detrimental are
2023-02-10
The reasons why antibiotic treatment may be detrimental are diverse. First, it may result in disruption of multifaceted microbe–microbe, as well as microbe–host, interactions that are key for the maintenance of homeostasis within this ecosystem. This can lead to the expansion of pathogenic microorga
-
phenanthroline br cDNA cloning gene structure and chromosoma
2023-02-09
cDNA cloning, gene structure and chromosomal localization The cDNA for the leukocyte-type 12S-lipoxygenase was first cloned from porcine leukocytes [9], and later from mouse [10], [11], rat [12], [13], bovine [14] and rabbit [15] sources. The cDNA for the platelet-type 12S-lipoxygenase cDNA has b
-
CTX0294885 For patients who have taken
2023-02-09
For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,
-
In the late s Solvay Pharmaceuticals discontinued the
2023-02-08
In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the
-
Our second patient years old male
2023-02-08
Our second patient, 42years old male, a farmer, was all right when he went to sleep, but noticed drooping of eyelids and swallowing difficulty when he woke up. He later developed flaccid weakness of all four limbs and was quadriplegic when he was wheeled into the emergency room. He was tachypneic an
-
br Experimental section br Results and discussion br Conclus
2023-02-08
Experimental section Results and discussion Conclusion Acknowledgements This work was financially supported by Recruitment Program of Global Experts, and the Director Foundation of XTIPC, CAS, Grant No. 2015RC011. This work was also financially supported by Natural Science Foundation of
-
The link between HPV infection and neoplasia has been
2023-02-08
The link between HPV infection and neoplasia has been well established. HPV encodes two oncogenes (E6 and E7) that drive CP 154526 receptor progression by controlling the functions of tumor suppressor proteins p53 and Rb [7]. HPV is associated with more than 99% of cervical CESC cases [8]. CESC rem
-
Many ruthenium complexes were tested as potential
2023-02-08
Many ruthenium complexes were tested as potential anticancer agents and two complexes, namely NAMI-A (trans-[imH] [RuCl4(dmso-S)(im)]; im, imidazole) and KP1019 (trans-[indH][RuCl4(ind)2]; ind, indazole) have successfully entered clinical trials [27], [28]. NAMI-A is selectively active against metas
-
The use of FTAI can overcome the negative impact of
2023-02-08
The use of FTAI can overcome the negative impact of low estrus detection efficiency, but implies effective synchrony of luteal function as well as synchronous growth and ovulation of a viable 86 5 follicle. Pregnancy rates obtained with FTAI may be comparable or better than those obtained after AI
15582 records 332/1039 page Previous Next First page 上5页 331332333334335 下5页 Last page